BioGeNe Series 2023: A Platform for Pharmaceutical, Biotechnology Professionals and Technology Providers (San Diego, United States – February 8-9, 2023) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “BioGeNe Series 2023” conference has been added to ResearchAndMarkets.com’s offering.

The host is here with a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2023 Confex on the 8th – 9th February 2023 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.

Drug discovery businesses have begun to invest in cutting-edge methods for biomarker discovery because of mounting demands related to the success rates of FDA-approved biomarkers and associated diagnostic tests.

Speakers are to discuss about Biomarker and Companion Diagnostics, Microbiome and Probiotics and Precision Medicine. In the past year, the genome editing sector has seen some impressive advancements in the fields of genome writing, base editing, and specific advancements in the treatments using Car-T cells and immunotherapy.

Numerous small innovative businesses are present in the market because of the growing emphasis on the development of probiotics products and drugs as well as human microbiome therapies.

Biomarker and Companion Diagnostics

• Immuno-Oncology
• Cancer Biomarkers
• Biomarker discovery/ development
• Translational research
• Clinical Biomarker
• Biomarkers in IO and Neurological disorders
• Imaging Biomarkers
• Pathology
• Companion Diagnostics

Next Gen Microbiome and Probiotics

• Microbiome discovery
• Department of Biochemistry and Immunology
• Microbiome science
• Microbiology
• Biological Science
• Gut Biology
• Human microbiome
• Drug discovery
• Therapeutics

Precision Medicine

• Personalized Medicine
• Digital Biomarkers
• Complex – Chronic – Rare Disease
• Genome Sequencing
• Artificial Intelligence and Machine Learning
• Translational Medicine
• Genomic Medicine
• Molecular Medicine
• Drug Discovery

What To Expect

Key Highlights

• Commercialization of CDx
• Proteomics and Genomics based Biomarkers
• Biomarker Drug Discovery and Assay Development
• Effective Microbiome Therapeutics in Production
• Role of the human skin microbiome in precision health
• The increasing pro-bacterial beauty industry
• Business collaborations- Regulations and Investments
• Novel horizons in biomarker strategies,
• Liquid biopsy-based disease detection
• Current Multi-Omics analysis
• Artificial Intelligence and Machine Learning
• Gene expression Profiling in Precision Medicine
• Multiplex Companion Diagnostics and Regulatory Guidelines
• Design of clinical trials in CDx
• Microbiome as a science and its clinical applications- skin, gut & women’s health
• Prebiotics, Probiotics and Postbiotics

Why Attend?

• To share and exchange the recent trends and techniques in Personalized Medicine
• Quality insights and cohesiveness of key issues and obstacles experienced by the healthcare providers while implementing Precision Medicine
• Discover the different avenues in patient-centric care
• Access a wide range of novel applications, innovative research, regulatory and policy development
• Opportunity for one-on-one networking and extend professional competency with experts ranging from Government, Industry, Technology, Research and Healthcare providers
• Be a part of the conversations via a panel discussion with a great lineup of experts

Who Should Attend:

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development, Translational Research, Clinical Biomarkers, Biomarkers in IO and Neurological disorders, Imaging Biomarkers, Pathology, Companion Diagnostics, Biomarker Imaging, Proteomics Biomarkers, Experimental Medicine, Data Science. Microbiome discovery, Department of Biochemistry and Immunology, Microbiome science, Microbiology, Biological Science, Gut Biology, Human microbiome, Drug discovery, Therapeutics, Immunotherapy

Industry: Pharma/Therapeutic Companies/Start Up’s

CEOs, CMO’s, CSO’s, COO’s, Presidents, Vice Presidents, Directors, Managing Directors, Head of Departments, Executive Leaders, Pharmacists, Oncologists, Immunologists, Geneticists, Principal Scientists, Big Data Scientists, Business Development, Regulatory and Policy Advisors, Diagnostic Laboratory Professionals, Global Leaders.

Departments: Oncology, Personalized medicine, Immunology, Molecular Biology, Genetics and genomic medicine, Molecular Medicine, Pharmacogenomics, Biotechnology

Academics: Universities, Research Institutes, Hospitals

Head of Departments, Professors, Lecturers, Senior Scientists, Researchers, Bioinformaticians

Departments: Oncology, Personalized medicine, Immunology, Molecular Biology, Genetics and genomic medicine, Molecular Medicine, Pharmacogenomics, Biotechnology

Speakers

Julius Goepp

Founder, CEO, Scaled Microbiomics

Maya Ivanjesku

Chief Scientific Officer, Dakota Biotech

Peter Leighton

CEO, ProSperity Bioscience

Seth D. Crosby

Director, Research Collaborations, Washington University School of Medicine

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

Emily Stein

CEO, Primal Health Inc.

Nicole M. Scott

CEO and Founder, Cybele Microbiome

Yug Varma

CEO, Phi Therapeutics

Larry Weiss

CEO and Founder, Persona Biome, Inc.

Leigh A. Frame

Associate Director, Resiliency & Well-being Center, Program Director, Integrative Medicine (INTM), Executive Director, Office of INTM & Health

Scott A. Jackson

Leader – Complex Microbial Systems Group, NIST – National Institute of Standards and Technology

Andrea Azcarate-Peril

Associate Professor of Medicine, Director, UNC Microbiome Core, School of Medicine, University of North Carolina at Chapel Hill

Shannon Muir

Co-director of the California Initiative to Advance Precision Medicine in the California Governor’s Office of Planning and Research,

Schott Cecilia

Global head Precision Medicine Diagnostics Novartis,

Manish Kohli

Huntsman Cancer Institute

Laura Dillon

Head of Translational Biomarkers, Parthenon Therapeutics

For more information about this conference visit https://www.researchandmarkets.com/r/2esiru

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900